The DCGI on Tuesday revoked its earlier order of suspending any new recruitment for phase two and three trial.
The permission however comes with a caveat. The DCGI has asked the company certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which has to be "scrupulously" followed by Serum Institute of India (SII).
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
Lok Sabha Elections#Elections With
- All
- Uttar Pradesh
- Maharashtra
- Tamil Nadu
- West Bengal
- Bihar
- Karnataka
- Andhra Pradesh
- Telangana
- Kerala
- Madhya Pradesh
- Rajasthan
- Delhi
- Other States
On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said it had resumed the trials for their coronavirus vaccine in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the ET ePaper online.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the ET ePaper online.